LuciaValenzuela Valenzuela

Dr. LuciaValenzuela Valenzuela

Universidad Autónoma de Baja California
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
OCOmar Cruz-Ramírez
Omar Cruz-Ramírez
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
ABAlberto Blanco-Salazar
Alberto Blanco-Salazar
JRJosé Antonio Rodriguez-Arenas
José Antonio Rodriguez-Arenas
PMParis Astrid Mier-Maldonado
Paris Astrid Mier-Maldonado
YTYanis Toledano-Magaña
Yanis Toledano-Magaña
Silver nanoparticles (AgNPs) not only have shown remarkable results as antimicrobial and antiviral agents but also as antitumor agents. This work reports the complete characterization of five polyvinylpyrrolidone-coated AgNP (PVP-AgNP) formulations, their cytotoxic activity against human colon tumor cells (HCT-15), their cytotoxic effect on primary mouse cultures, and their lethal dose on BALB/c mice. The evaluated AgNP formulations have a composition within the ranges Ag: 1.14–1.32% w/w, PVP: 19.6–24.5% and H2O: 74.2–79.2% with predominant spherical shape within an average size range of 16–30 nm according to transmission electron microscopy (TEM). All formulations assessed increase mitochondrial ROS concentration and induce apoptosis as the leading death pathway on HCT-15 cells. Except for AgNP1, the growth inhibition potency of AgNP formulations of human colon tumor cancer cells (HCT-15) is 34.5 times higher than carboplatin, one of the first-line chemotherapy agents. Nevertheless, 5–10% of necrotic events, even at the lower concentration evaluated, were observed. The cytotoxic selectivity was confirmed by evaluating the cytotoxic effect on aorta, spleen, heart, liver, and kidney primary cultures from BALB/c mice. Despite the cytotoxic effects observed in vitro, the lethal dose and histopathological analysis showed the low toxicity of these formulations (all of them on Category 4 of the Globally Harmonized System of Classification and Labelling of Chemicals) and minor damage observed on analyzed organs. The results provide an additional example of the rational design of safety nanomaterials with antitumor potency and urge further experiments to complete the preclinical studies for these AgNP formulations.

7 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
ABAlberto Blanco-Salazar
Alberto Blanco-Salazar
JPJesús David Perrusquía-Hernández
Jesús David Perrusquía-Hernández
MNMario Nequiz-Avendaño
Mario Nequiz-Avendaño
PMParis Astrid Mier-Maldonado
Paris Astrid Mier-Maldonado
NBNina Bogdanchikova
Nina Bogdanchikova
Nanomaterials quickly evolve to produce safe and effective biomedical alternatives, mainly silver nanoparticles (AgNPs). The AgNPs’ antibacterial, antiviral, and antitumor properties convert them into a recurrent scaffold to produce new treatment options. This work reported the full characterization of a highly biocompatible protein-coated AgNPs formulation and their selective antitumor and amoebicidal activity. The protein-coated AgNPs formulation exhibits a half-inhibitory concentration (IC50) = 19.7 µM (2.3 µg/mL) that is almost 10 times more potent than carboplatin (first-line chemotherapeutic agent) to inhibit the proliferation of the highly aggressive human adenocarcinoma HCT-15. The main death pathway elicited by AgNPs on HCT-15 is apoptosis, which is probably stimulated by reactive oxygen species (ROS) overproduction on mitochondria. A concentration of 111 µM (600 µg/mL) of metallic silver contained in AgNPs produces neither cytotoxic nor genotoxic damage on human peripheral blood lymphocytes. Thus, the AgNPs formulation evaluated in this work improves both the antiproliferative potency on HCT-15 cultures and cytotoxic selectivity ten times more than carboplatin. A similar mechanism is suggested for the antiproliferative activity observed on HM1-IMSS trophozoites (IC50 = 69.2 µM; 7.4 µg/mL). There is no change in cell viability on mice primary cultures of brain, liver, spleen, and kidney exposed to an AgNPs concentration range from 5.5 µM to 5.5 mM (0.6 to 600 µg/mL). The lethal dose was determined following the OECD guideline 420 for Acute Oral Toxicity Assay, obtaining an LD50 = 2618 mg of Ag/Kg body weight. All mice survived the observational period; the histopathology and biochemical analysis show no differences compared with the negative control group. In summary, all results from toxicological evaluation suggest a Category 5 (practically nontoxic) of the Globally Harmonized System of Classification and Labelling of Chemicals for that protein-coated AgNPs after oral administration for a short period and urge the completion of its preclinical toxicological profile. These findings open new opportunities in the development of selective, safe, and effective AgNPs formulations for the treatment of cancer and parasitic diseases with a significant reduction of side effects.

8 April 2025 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
GPGraciela Lizeth Pérez-González
Graciela Lizeth Pérez-González
Luis Jesús Villarreal-GómezLuis Jesús Villarreal-Gómez
Luis Jesús Villarreal-Gómez
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
EMEdgar Ramiro Méndez-Sánchez
Edgar Ramiro Méndez-Sánchez
Jose Cornejo-BravoJose Cornejo-Bravo
Jose Cornejo-Bravo
Introduction: There is a strong need for drug delivery systems that are both highly compatible with biological tissues and effective when used in the oral mucosa. While gels, creams, or ointments are currently employed for this purpose, their oral bioavailability is constrained by the limited contact time with mucosal tissue. Method: In response to this challenge, we developed and evaluated the efficacy of a multilayer mucoadhesive system incorporated with Dexamethasone Sodium Phosphate (DEX-P) for oral mucosal delivery. An electrospun multilayer system was created and subjected to biocompatibility and efficiency testing through both in vitro and ex vivo approaches, finally culminating in an acceptability trial in healthy human volunteers. The multilayer system was created using Poly-Vinyl Pyrrolidone (PVP) and Poly ε-Caprolactone (PCL) as a polymeric base and Polycarbophil (NOVEON® AA-1, PCF) serving as an adhesion enhancer to facilitate the unidirectional release of Dexamethasone Sodium Phosphate (DEX-P). Result: The nanofibers matrices underwent morphological characterization by Scanning Electron Microscopy (SEM), and DEX-P release was evaluated using ex vivo porcine mucosa, yielding promising results. In vitro cytotoxicity was evaluated through the MTT assay, employing HFF-1 cells. The cell viability ranged from 78 to 96%, suggesting the safety of the polymers used. The tested dose range of DEX on cell lines did not decrease below 75%, indicating its safety in terms of in vivo cytotoxicity. Biocompatibility was evaluated on animal models, with no considerable tissue damage observed. Conclusion: Human in vivo studies demonstrated prolonged adhesion and a favorable perception of the system.

15 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PMParis Astrid Mier-Maldonado
Paris Astrid Mier-Maldonado
EMEdgar Ramiro Méndez-Sánchez
Edgar Ramiro Méndez-Sánchez
NBNina Bogdanchikova
Nina Bogdanchikova
JGJuan Carlos García-Ramos
Juan Carlos García-Ramos
YTYanis Toledano-Magaña
Yanis Toledano-Magaña
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
Background/Objectives: Silver nanoparticles (AgNPs) hold great promise for antimicrobial, antiviral, and anticancer applications; however, concerns about their toxicity remain a major barrier to their medical use. This study systematically evaluates the acute oral toxicity of five well-characterized AgNP formulations from the Argovit™ family, which previously showed remarkable biomedical properties. Methods: We determine the median lethal dose (LD50), assess clinical signs, and identify the histopathological alterations in mice following oral administration for each formulation. The LD50 was calculated for AgNPs (metallic silver plus stabilizing agent) and for the complete formulation (including water). Results: All formulations showed exceptionally high LD50 values (86,020–150,535 mg/kg) considering the complete formulation, surpassing those reported for other AgNPs in the literature (typically ≤5,000 mg/kg). Clinical signs and toxicological assessment reveal differences in the response of the AgNPs formulations, but all exhibit extremely low toxicity. Histopathological changes were minimal compared to those caused by other AgNP formulations, even though we used doses several times higher. The estimated human LD50 values for the assessed Argovit AgNPs formulations are 17-30 times higher than those reported for other AgNP formulations in the literature. Conclusions: The remarkably low toxicity found in this work contradicts the prevailing assumption that only biogenically synthesized AgNP are biocompatible, highlighting these synthetic PVP-AgNP formulations as a highly safe alternative. The study suggests that the low LD50 may be due to the peculiar structure of Argovit AgNP formulations, which, according to recent data, consists of Ag cores incorporated into PVP nano- and microgels. A high percentage of rapid elimination of Argovit AgNPs from organisms (>98%) via feces also contributes to low LD50. To our knowledge, the present work is the first to study the LD50 of AgNPs-nanogel systems.

13 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NRNodari Rizun
Nodari Rizun
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
CRCarlos Rodríguez-Escobar
Carlos Rodríguez-Escobar
GPGraciela Lizeth Pérez-González
Graciela Lizeth Pérez-González
RVRicardo Valdez
Ricardo Valdez
Luis Jesús Villarreal-GómezLuis Jesús Villarreal-Gómez
Luis Jesús Villarreal-Gómez
Background: Shilajit, a natural mineral exudate utilized for centuries in traditional Ayurvedic and Eastern European medicine, is regarded as a traditional adaptogenic substance and rejuvenator. This systematic review synthesizes contemporary scientific evidence regarding the biomedical applications of Shilajit extract, critically evaluating its pharmacological properties and therapeutic potential. Methods: A systematic search was performed across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed literature published between 1951 and 2026. Studies were screened against rigorous eligibility criteria, and methodological quality was appraised using the Cochrane Risk of Bias 2.0 and SYRCLE tools. Results: Studies were included in the final analysis. Characterized by high concentrations of fulvic acid and dibenzo-α-pyrones, Shilajit exhibits antioxidant activity, anti-inflammatory, neuroprotective, and adaptogenic activities. Preclinical data demonstrate dose-dependent cytotoxicity against multiple cancer cell lines via apoptosis induction. Furthermore, evidence suggests its efficacy in enhancing muscular strength, improving reproductive function, and mitigating protein aggregation in neurodegenerative contexts. Conclusions: Shilajit possesses significant biomedical potential that aligns with its traditional applications. However, clinical integration requires addressing standardization challenges, implementing stringent quality control to mitigate heavy metal risks, and conducting large-scale human trials to definitively establish safety and efficacy profiles.

11 August 2023 in Molecules
Verified
Journal Article
Open access
PDF file
YTYanis Toledano-Magaña
Yanis Toledano-Magaña
MNMario Néquiz
Mario Néquiz
LuciaValenzuela ValenzuelaLuciaValenzuela Valenzuela
LuciaValenzuela Valenzuela
JSJessica J. Sánchez-García
Jessica J. Sánchez-García
RGRodrigo Galindo-Murillo
Rodrigo Galindo-Murillo
EKElena Klimova
Elena Klimova
Amoebiasis is the second leading cause of death worldwide associated with parasitic disease and is becoming a critical health problem in low-income countries, urging new treatment alternatives. One of the most promising strategies is enhancing the redox imbalance within these susceptible parasites related to their limited antioxidant defense system. Metal-based drugs represent a perfect option due to their extraordinary capacity to stabilize different oxidation states and adopt diverse geometries, allowing their interaction with several molecular targets. This work describes the amoebicidal activity of five 2-(Z-2,3-diferrocenylvinyl)-4X-4,5-dihydrooxazole derivatives (X = H (3a), Me (3b), iPr (3c), Ph (3d), and benzyl (3e)) on Entamoeba histolytica trophozoites and the physicochemical, experimental, and theoretical properties that can be used to describe the antiproliferative activity. The growth inhibition capacity of these organometallic compounds is strongly related to a fine balance between the compounds’ redox potential and hydrophilic character. The antiproliferative activity of diferrocenyl derivatives studied herein could be described either with the redox potential, the energy of electronic transitions, logP, or the calculated HOMO–LUMO values. Compound 3d presents the highest antiproliferative activity of the series with an IC50 of 23 µM. However, the results of this work provide a pipeline to improve the amoebicidal activity of these compounds through the directed modification of their electronic environment.